Thrombolysis during extended cardiopulmonary resuscitation for autoimmune-related XXXX .

@entity1 @entity548 @entity49 @entity1151 @entity5506 @entity1167 @entity583 @entity792
BACKGROUND: @entity1151 ( @entity1151 ) and @entity583 are the two most common causes of @entity1167 ( @entity1167 ). At present, lethal @entity548 makes thrombolytic therapy underused during cardiopulmonary resuscitation, despite the potential benefits for these underlying conditions. @entity49 of the blood in @entity792 (such as @entity5506 ) carries a risk of @entity1151 . It is critical to find out the etiology of @entity1167 for timely thrombolytic intervention. METHODS: A 23-year-old @entity1 with a 10-year medical history of @entity5506 suffered from @entity1167 in our emergency intensive care unit. ECG and echocardiogram indicated the possibility of @entity1151 , so fibrinolytic therapy (alteplase) was successful during prolonged resuscitation. RESULTS: Neurological recovery of the @entity1 was generally good, and no fatal @entity548 developed. @entity1151 was documented by CT pulmonary angiography. CONCLUSIONS: A medical history of @entity792 poses a risk of PE, and the causes of @entity1167 (such as this) should be investigated etiologically. A therapy with alteplase may be used early during cardiopulmonary resuscitation once there is presumptive evidence of PE. Clinical trials are needed in this setting to study @entity1 with @entity49 states.
